Key Takeaways
- CardioKol’s AI platform passively monitors routine phone conversations to detect early signs of atrial fibrillation, a condition whose timely identification can avert the majority of stroke‑related complications.
- Founded in 2017, the startup built a protected technology base—granted patents in the U.S., Japan, and Israel—and assembled a large, hospital‑validated database of speech recordings paired with ECG signals.
- Despite the medical promise, the company could not secure the financing needed in 2023 to launch agreed‑upon commercial pilots in Europe and Asia, triggering a cash‑flow crisis.
- By the end of 2024 most staff had been laid off or resigned, and the firm filed for insolvency in the Central District Court, reporting accumulated losses exceeding NIS 19 million (≈US$6.3 million).
- The filing reveals current liabilities of about NIS 379,000 and a contingent liability of roughly $1.89 million tied to grants from the Israel Innovation Authority.
- Founder‑provided loans, chiefly from the French healthcare fund Kamet Ventures, have kept the minimal operations alive while the insolvency process unfolds.
Overview and Technology
CardioKol emerged as a digital‑health innovator with a novel approach to cardiac screening: an artificial‑intelligence algorithm that listens, in the background, to ordinary telephone conversations and extracts subtle vocal biomarkers indicative of atrial fibrillation (AF). AF is a prevalent arrhythmia that, when undetected, significantly raises the risk of stroke, heart failure, and other cardiovascular events. By flagging the earliest electrophysiological changes through voice analysis, CardioKol aimed to enable preventive interventions before a clinical event occurs, potentially averting more than 70 % of AF‑related complications. The technology’s non‑intrusive nature—requiring no wearable devices or clinic visits—made it especially attractive for older adults who may be reluctant or unable to adopt conventional monitoring tools.
Founding and Development
Launched in 2017 by a team of clinicians, data scientists, and entrepreneurs, CardioKol set out to translate years of research on speech‑cardiac correlations into a market‑ready product. Early proof‑of‑concept studies demonstrated that machine‑learning models trained on thousands of voice‑ECG pairs could achieve sensitivities and specificities comparable to standard Holter monitoring. Encouraged by these results, the company proceeded to refine its algorithms, integrate them into a lightweight smartphone application, and begin building the infrastructure necessary for large‑scale deployment. The founders envisioned a subscription‑based service that could be offered through telecom providers, insurance companies, or directly to consumers seeking proactive heart health management.
Intellectual Property and Clinical Data
To safeguard its core innovation, CardioKol pursued an aggressive patent strategy, securing granted patents in key jurisdictions including the United States, Japan, and Israel. These patents cover the signal‑processing methods, feature‑extraction techniques, and decision‑logic used to infer cardiac rhythm from speech patterns. Parallel to IP development, the company amassed a substantial clinical repository: hundreds of thousands of anonymized speech recordings synchronized with contemporaneous ECG tracings, collected in partnership with leading hospitals in Israel and abroad. This database not only served as the training ground for its AI models but also provided a valuable asset for future research collaborations, regulatory submissions, and potential licensing deals.
Commercial Aspirations and Partnerships
CardioKol’s go‑to‑market plan centered on pilot projects with strategic customers across Europe and Asia. Telecommunications operators, attracted by the prospect of adding a health‑monitoring layer to their services, had signed letters of intent to trial the platform on a subset of their subscriber base. Similarly, several Asian health‑insurance entities expressed interest in integrating the tool into preventive‑care programs, anticipating reduced claims costs from stroke avoidance. The pilots were designed to generate real‑world efficacy data, refine user experience, and pave the way for broader commercial rollout. Success in these early engagements was seen as critical for attracting the series‑B financing needed to scale production, obtain regulatory clearances (such as CE marking and FDA clearance), and build a sales organization.
Financial Struggles and Funding Gap
Despite the promising pipeline, CardioKol encountered a severe financing shortfall in 2023. The anticipated round of venture capital, expected to fund the pilot launches and subsequent market expansion, failed to materialize due to a combination of investor risk aversion toward early‑stage digital‑health assets and a broader tightening of global tech funding. Without the necessary capital, the company could not honor the financial commitments tied to its agreed pilots, causing partners to postpone or cancel their trials. The resulting revenue vacuum forced CardioKol to adopt austerity measures: delaying non‑essential expenditures, suspending hiring, and cutting back on research activities. By mid‑2024, the cash runway had dwindled to a point where sustaining even a minimal workforce became untenable.
Operational Scale‑back and Workforce Reductions
The financial strain precipitated a progressive scaling back of operations. Throughout 2024, CardioKol laid off the majority of its engineering, clinical, and administrative staff. Senior leadership, including the chief executive officer and chief technology officer, either resigned or transitioned to advisory roles as the company shifted to a caretaker mode. Only a skeleton team remained to maintain essential functions such as data security, IP maintenance, and limited communication with stakeholders. This reduction not only impaired the company’s ability to advance product development but also diminished its credibility with potential partners who questioned the viability of a minimally staffed startup.
Insolvency Filing Details
In light of its untenable financial position, CardioKol filed an application with the Central District Court to initiate insolvency proceedings. The petition, submitted by attorney Shay Bar‑Nir of Piron & Co., outlines the company’s economic distress and seeks legal protection while a restructuring or liquidation process unfolds. According to the filing, CardioKol has accumulated losses surpassing NIS 19 million (approximately US$6.3 million) since its inception in 2017. As of the close of 2024, the firm’s current liabilities stood at roughly NIS 379,000, reflecting outstanding obligations to vendors, service providers, and minor creditors. The court’s involvement aims to orderly address these debts while assessing the possibility of rescuing the core technology or its underlying assets.
Liabilities and Contingent Obligations
Beyond the immediate payables, the insolvency petition highlights a significant contingent liability amounting to about $1.89 million. This figure stems from grants previously awarded by the Israel Innovation Authority (IIA), a governmental body that supports innovative ventures through non‑dilutive funding. Such grants often carry repayment or royalty obligations if the recipient fails to meet predefined milestones or ceases operations. CardioKol’s inability to advance toward commercialization triggered these conditions, exposing the firm to a potential claim from the IIA. Managing this contingent liability will be a critical factor in any restructuring plan, as it could substantially affect the net value available to creditors or investors.
Founder‑Backed Bridge Financing
To keep the lights on while navigating insolvency, CardioKol has relied on temporary financing from its founders. The largest shareholder, French healthcare‑investment fund Kamet Ventures, has extended a series of founder loans designed to preserve the company’s essential assets—particularly its IP portfolio and clinical database—during the legal process. These bridge facilities, while insufficient to fund a full‑scale relaunch, have enabled the maintenance of data integrity, payment of minimal hosting costs, and continued communication with potential acquirers or partners interested in acquiring the technology or its data assets. The founder loans also signal the founders’ belief in the underlying value of the innovation, even as the corporate entity confronts financial distress.
Prospects and Industry Implications
CardioKol’s situation underscores the inherent risks facing early‑stage digital‑health companies that depend on lengthy regulatory pathways and uncertain reimbursement models. While the scientific premise—using ubiquitous phone conversations for cardiac screening—holds considerable promise, translating that promise into sustainable revenue remains challenging without robust payer relationships and clear regulatory clearance. The outcome of the insolvency proceedings will likely determine whether CardioKol’s technology is acquired by a larger health‑tech or telecom entity, licensed to third parties, or eventually abandoned. For the broader industry, the case serves as a cautionary tale about aligning fundraising timelines with product‑development milestones, securing non‑dilutive grant compliance, and constructing realistic commercialization pathways that can attract follow‑on investment even in volatile funding climates.